Osaka Acute Coronary Insufficiency Study (OACIS) Group. Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction
-
- Matsumoto Sen
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Nakatani Daisaku
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Sakata Yasuhiko
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Suna Shinichiro
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Shimizu Masahiko
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Usami Masaya
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Hara Masahiko
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Sumitsuji Satoru
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Nanto Shinsuke
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
-
- Sasaki Tatsuya
- Cardiovascular Division, Osaka Minami Medical Center, National Hospital Organization
-
- Hamasaki Toshimitsu
- Department of Biomedical Statistics, Osaka University Graduate School of Medicine
-
- Sato Hiroshi
- School of Human Welfare Studies Health Care Center and Clinic Kwansei Gakuin University
-
- Hori Masatsugu
- Osaka Medical Center for Cancer and Cardiovascular Diseases
-
- Komuro Issei
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine
書誌事項
- タイトル別名
-
- Elevated Serum Heart-Type Fatty Acid-Binding Protein in the Convalescent Stage Predicts Long-Term Outcome in Patients Surviving Acute Myocardial Infarction
この論文をさがす
抄録
Background: Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients. Methods and Results: A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03–3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15–5.39, P=0.020). Conclusions: Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients. (Circ J 2013; 77: 1026–1032)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 77 (4), 1026-1032, 2013
一般社団法人 日本循環器学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680080126592
-
- NII論文ID
- 10031139007
-
- NII書誌ID
- AA11591968
-
- COI
- 1:STN:280:DC%2BC3s3ntVeisw%3D%3D
-
- ISSN
- 13474820
- 13469843
-
- PubMed
- 23291993
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可